The acquisition of Immunomedics "represents significant progress in Gilead’s work to build a strong and diverse oncology portfolio."
"Close coordination of remdesivir manufacturing will be critical," said Gilead Sciences.
The deal adds to Gilead's presence in immuno-oncology, an approach to treating cancer that harnesses the body's immune system.
Home Depot, Gilead Sciences, Argonne National Lab, Globe Photos, American Water, Talos Energy, Ryan Cos., Insurance Auto Actions, VIQ Solutions, Trinseo
Each year dozens of shareholder proposals seek to quash potential conflicts of interest by calling for an independent chair. But they hardly ever pass.
The $11.9 billion acquisition gives Gilead access to the oncology market as its hepatitis C drugs face declining sales.
The flurry of deals came after issuance virtually halted for nearly two weeks.
A biotech finance chief shares her thoughts on the CFO role.
